IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF

A pharmaceutical composition, comprising an effective amount of a compound as shown in in Formula (I) or a stereoisomer, tautomer, deuterated compound, oxynitride, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in Formula (I):

• wherein
• X is C, N, or O;
• X1, X2, X3, and X4 are respectively C or N, X1 is different from X2, X1 is different from X4, and X2 is different from X3;
• R1 and R2 are independently H, deuterium, C1-6 alkyl, C3-12 carbocyclyl, C3-12 carbocyclyl-C1-4 alkylene, heterocyclyl composed of 3-12 atoms, (heterocyclyl composed of 3-12 atoms)-C1-4 alkylene, C6-10 aryl, C6-10 aryl-C1-4 alkylene, heteroaryl composed of 5-14 atoms, or (heteroaryl composed of 5-14 atoms)-C1-4 alkylene, or R1, R2 and X connected thereto form a C3-12 carbon ring or a heterocyclic ring composed of 3-12 atoms, and wherein the C1-6 alkyl, the C3-12 carbocyclyl, the C3-12 carbocyclyl-C1-4 alkylene, the heterocyclyl composed of 3-12 atoms, the (heterocyclyl composed of 3-12 atoms)-C1-4 alkylene, the C6-10 aryl, the C6-10 aryl-C1-4 alkylene, the heteroaryl composed of 5-14 atoms, the (heteroaryl composed of 5-14 atoms)-C1-4 alkylene, or the C3-12 carbon ring or the heterocyclic ring composed of 3-12 atoms formed by R1, R2 and X connected thereto are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 R′;
• R3 is C6-10 aryl or heteroaryl composed of 5-10 atoms, wherein the C6-10 aryl and the heteroaryl composed of 5-10 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 R″;
• R4 is H, deuterium, F, Cl, Br, CN, NO2, —ORa, —NRbRc, or C1-6 alkyl;
• R′ and R″ are independently H, deuterium, F, Cl, Br, CN, NO2, ═O, —ORa, —NRbRc, —S(═O)2Ra, C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, or heterocyclyl composed of 3-12 atoms, wherein the C1-6 alkyl, the C3-8 cycloalkyl, the C3-8 cycloalkenyl and the heterocyclyl composed of 3-12 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 first substituents, and the first substituents are independently deuterium, F, Cl, Br, CN, ═O, —ORa, —NRbRc, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, or —CO—NRbRc;
• and
• Ra, Rb, and Rc are independently H, deuterium, C1-6 alkyl, C1-6 haloalkyl, or heterocyclyl composed of 3-6 atoms, or Rb, Rc and nitrogen atoms connected thereto form a heterocyclic ring composed of 3-6 atoms, wherein the C1-6 alkyl and the heterocyclic ring composed of 3-6 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 second substituents, and the second substituents are independently deuterium, F, Cl, CN, OH, NH2, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C1-6 alkylamino.

A method for inhibiting Lysine specific demethylase 1 (LSD1), comprising administering, to a cell to be treated, a compound or a pharmaceutical composition comprising an effective amount of the compound, wherein the cell to be treated expresses LSD1, and the compound is as shown in in Formula (I) or a stereoisomer, tautomer, deuterated compound, oxynitride, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in Formula (I):

• wherein
• X is C, N, or O;
• X1, X2, X3, and X4 are respectively C or N, X1 is different from X2, X1 is different from X4, and X2 is different from X3;
• R1 and R2 are independently H, deuterium, C1-6 alkyl, C3-12 carbocyclyl, C3-12 carbocyclyl-C1-4 alkylene, heterocyclyl composed of 3-12 atoms, (heterocyclyl composed of 3-12 atoms)-C1-4 alkylene, C6-10 aryl, C6-10 aryl-C1-4 alkylene, heteroaryl composed of 5-14 atoms, or (heteroaryl composed of 5-14 atoms)-C1-4 alkylene, or R1, R2 and X connected thereto form a C3-12 carbon ring or a heterocyclic ring composed of 3-12 atoms, and wherein the C1-6 alkyl, the C3-12 carbocyclyl, the C3-12 carbocyclyl-C1-4 alkylene, the heterocyclyl composed of 3-12 atoms, the (heterocyclyl composed of 3-12 atoms)-C1-4 alkylene, the C6-10 aryl, the C6-10 aryl-C1-4 alkylene, the heteroaryl composed of 5-14 atoms, the (heteroaryl composed of 5-14 atoms)-C1-4 alkylene, or the C3-12 carbon ring or the heterocyclic ring composed of 3-12 atoms formed by R1, R2 and X connected thereto are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 R′;
• R3 is C6-10 aryl or heteroaryl composed of 5-10 atoms, wherein the C6-10 aryl and the heteroaryl composed of 5-10 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 R″;
• R4 is H, deuterium, F, Cl, Br, CN, NO2, —ORa, —NRbRc, or C1-6 alkyl;
• R′ and R″ are independently H, deuterium, F, Cl, Br, CN, NO2, ═O, —ORa, —NRbRc, —S(═O)2Ra, C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, or heterocyclyl composed of 3-12 atoms, wherein the C1-6 alkyl, the C3-8 cycloalkyl, the C3-8 cycloalkenyl and the heterocyclyl composed of 3-12 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 first substituents, and the first substituents are independently deuterium, F, Cl, Br, CN, ═O, —ORa, —NRbRc, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, or —CO—NRbRc;
• and
• Ra, Rb, and Rc are independently H, deuterium, C1-6 alkyl, C1-6 haloalkyl, or heterocyclyl composed of 3-6 atoms, or Rb, Rc and nitrogen atoms connected thereto form a heterocyclic ring composed of 3-6 atoms, wherein the C1-6 alkyl and the heterocyclic ring composed of 3-6 atoms are independently unsubstituted or substituted with 1, 2, 3, or 4 second substituents, and the second substituents are independently deuterium, F, Cl, CN, OH, NH2, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C1-6 alkylamino.